Cargando…

Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies

BACKGROUND: The idiopathic inflammatory myopathies (IIM) are autoimmune diseases characterised by acquired proximal muscle weakness, inflammatory cell infiltrates in muscle and myositis-specific/associated autoantibodies. It is unclear which pathways are involved in IIM, and the functional relations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parkes, Joanna E., Rothwell, Simon, Day, Philip J., McHugh, Neil J., Betteridge, Zoë E., Cooper, Robert G., Ollier, William E., Chinoy, Hector, Lamb, Janine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936183/ https://www.ncbi.nlm.nih.gov/pubmed/27388770 http://dx.doi.org/10.1186/s13075-016-1061-7

Ejemplares similares

Recent advances in the immunogenetics of idiopathic inflammatory myopathy
por: Chinoy, Hector, et al.
Publicado: (2011)

Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis
por: Rothwell, Simon, et al.
Publicado: (2019)

MicroRNA and mRNA profiling in the idiopathic inflammatory myopathies
por: Parkes, Joanna E., et al.
Publicado: (2020)

Genetic association study of NF-κB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy
por: Chinoy, Hector, et al.
Publicado: (2012)

The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis
por: Oldroyd, Alexander, et al.
Publicado: (2019)

The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort
por: Parker, Matthew J S, et al.
Publicado: (2019)

Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis: Reply
por: Oldroyd, Alexander, et al.
Publicado: (2019)

Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: a 10-year epidemiological study
por: Parker, Matthew J S, et al.
Publicado: (2018)

Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis
por: Parkes, Joanna E., et al.
Publicado: (2018)

Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies
por: Leclair, Valérie, et al.
Publicado: (2023)

Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients
por: Betteridge, Z., et al.
Publicado: (2019)

Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer
por: Betteridge, Zoe E., et al.
Publicado: (2018)

Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies
por: Oldroyd, Alexander, et al.
Publicado: (2018)

Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis
por: Gunawardena, H, et al.
Publicado: (2009)

Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies
por: Mahler, Michael, et al.
Publicado: (2019)

A review of accelerometer-derived physical activity in the idiopathic inflammatory myopathies
por: Oldroyd, Alexander, et al.
Publicado: (2019)

Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study
por: Chinoy, H, et al.
Publicado: (2011)

Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis
por: Betteridge, Zoe, et al.
Publicado: (2020)

The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients
por: Tansley, Sarah L, et al.
Publicado: (2020)

Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria
por: To, Fergus, et al.
Publicado: (2019)

Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies
por: Lilleker, James B, et al.
Publicado: (2018)

8.4 Novel autoantibodies targeting a p140 protein are a major autoantigen system in juvenile dermatomyositis and a marker of calcinosis
por: Gunawardena, H, et al.
Publicado: (2008)

Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods – a qualitative study
por: Oldroyd, Alexander, et al.
Publicado: (2020)

A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies
por: Oldroyd, Alexander G S, et al.
Publicado: (2021)

Novel autoantibodies and clinical phenotypes in adult and juvenile myositis
por: Betteridge, Zoe E, et al.
Publicado: (2011)

Corrigendum to: A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies
por: Oldroyd, Alexander G S, et al.
Publicado: (2021)

Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results
por: To, Fergus, et al.
Publicado: (2020)

Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app
por: Oldroyd, Alexander G S, et al.
Publicado: (2022)

Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis
por: Párraga Prieto, Cristina, et al.
Publicado: (2020)

The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity
por: Tansley, Sarah L, et al.
Publicado: (2020)

Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis
por: Megremis, Spyridon, et al.
Publicado: (2020)

Cardiovascular manifestations in idiopathic inflammatory myopathies
por: Shah, Meera, et al.
Publicado: (2023)

Association of an MHC Class II Haplotype with Increased Risk of Polymyositis in Hungarian Vizsla Dogs
por: Massey, Jonathan, et al.
Publicado: (2013)

British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy
por: Oldroyd, Alexander G S, et al.
Publicado: (2022)

Aberrant Expression of High Mobility Group Box Protein 1 in the Idiopathic Inflammatory Myopathies
por: Day, Jessica, et al.
Publicado: (2020)

Analysis of human total antibody repertoires in TIF1γ autoantibody positive dermatomyositis
por: Megremis, Spyridon, et al.
Publicado: (2021)

Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features
por: Yasin, S. A., et al.
Publicado: (2019)

The EuroMyositis registry: an international collaborative tool to facilitate myositis research
por: Lilleker, James B, et al.
Publicado: (2018)

Familial autoimmunity in patients with idiopathic inflammatory myopathies
por: Che, Weng Ian, et al.
Publicado: (2022)

Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
por: Akram, Qasim, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4pubs625k8j09kvj1olnaupip7